BioCryst

Through groundbreaking technology, we are revolutionizing the treatment of rare and serious diseases at BioCryst Pharmaceuticals. Founded in 1986 as a spin-off from the University of Alabama at Birmingham research, BioCryst has a rich history of scientific innovation and a steadfast commitment to patients. As world leaders in structure-guided drug design, we leverage our deep understanding of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop novel small-molecule drugs that block key enzymes involved in the pathogenesis of diseases. This pioneering approach allows us to create first-in-class or best-in-class oral therapeutics for conditions where there is a significant unmet medical need.

Our innovation focus is exemplified by the development and commercialization of ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor for preventing hereditary angioedema (HAE) attacks. This breakthrough medicine represents a significant advancement for HAE patients, offering a convenient and effective prophylactic treatment. Beyond HAE, our robust pipeline includes promising candidates for other complement-mediated diseases and various rare conditions. We are continuously exploring new frontiers in drug discovery, driven by our passion to deliver medicines that can profoundly impact patients' lives. Our Discovery Center of Excellence in Birmingham, Alabama, remains at the heart of our research endeavors, working in synergy with our global teams to translate scientific insights into tangible therapeutic solutions. At BioCryst, we are not just developing drugs; we are dedicated to empowering patients and reshaping the landscape of rare disease treatment through relentless innovation and a patient-centric approach.